08:29 AM EDT, 03/24/2026 (MT Newswires) -- Karyopharm Therapeutics ( KPTI ) said Tuesday that its experimental therapy, selinexor, in combination with ruxolitinib for treating patients with frontline myelofibrosis, met the first co-primary endpoint in a phase 3 study.

The company said the study showed the combination significantly reduced spleen size, with 50% of patients achieving a meaningful reduction at 24 weeks compared with 28% for ruxolitinib alone.

Patients on the combination also experienced faster and longer-lasting improvements, the company said, adding that symptom improvements were similar between the two groups, but early data suggest a potential benefit in overall survival.

The therapy also showed signs of affecting the disease at a molecular level, with more patients experiencing reductions in key genetic markers.

Karyopharm Therapeutics ( KPTI ) said it plans to meet with the US Food and Drug Administration to discuss the trial results and its supplemental marketing application filing.

Additional data are expected to be presented in H2 2026, it added.

Separately, the company said it agreed with RA Capital Management to raise about $30 million through a private placement, with potential additional proceeds of $44 million if accompanying warrants are exercised.

The company said the deal includes the sale of common stock, pre-funded warrants, and accompanying warrants exercisable at $10 per share.

Proceeds from the placement, expected to close Thursday, will be used for general corporate purposes, including ongoing and planned clinical trials, the company added.